semax vs pe-22-28
semax (B-tier) vs pe-22-28 (C-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.
semax · tier B
russian nootropic. approved there, not here. for focus, stroke recovery, and cognitive decline. real mechanism, thin US trials.
Russian nootropic. approved there since the 1990s. BDNF upregulation within 30 minutes of an intranasal dose, effect persists 24+ hours.
Russia '82 stroke registry · half-life minutes in plasma; effects persist for hours due to CNS penetration and BDNF induction cascade · focus
pe-22-28 · tier C
a seven amino acid peptide researched as an antidepressant, so far only in mice and in cells. three papers, one lab, zero humans, and the 23 hour duration printed on vendor pages was measured on a different molecule.
a seven amino acid peptide researched as an antidepressant. it blocks a potassium channel called TREK-1, and blocking that channel makes mice behave the way antidepressant drugs make them behave. the cell work runs a proper dose-response curve and the mouse results repeat, but every original paper comes from one CNRS lab, no human has ever received it, and how long it lasts in the body is unpublished.
3 papers · zero humans · half-life not published. no pharmacokinetic study of PE 22-28 exists, and the origin paper reports no serum half-life number for it. the 23 h figure quoted by vendors is a behavioural half-effect time measured on the biotinylated alanine analog at 40 mcg/kg · focus
at a glance
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.